APA (7th ed.) Citation

Cui, Y., Qiu, T., Wang, J., Liu, X., Luo, L., Yin, J., . . . Ren, S. (2025). IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC. Molecular Cancer, 24(1), 1. https://doi.org/10.1186/s12943-025-02383-x

Chicago Style (17th ed.) Citation

Cui, Yanan, et al. "IFITM3 Enhances Immunosensitivity via MHC-I Regulation and Is Associated with the Efficacy of Anti-PD-1/-L1 Therapy in SCLC." Molecular Cancer 24, no. 1 (2025): 1. https://doi.org/10.1186/s12943-025-02383-x.

MLA (9th ed.) Citation

Cui, Yanan, et al. "IFITM3 Enhances Immunosensitivity via MHC-I Regulation and Is Associated with the Efficacy of Anti-PD-1/-L1 Therapy in SCLC." Molecular Cancer, vol. 24, no. 1, 2025, p. 1, https://doi.org/10.1186/s12943-025-02383-x.